Catch Them. You Can.


PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]

Prevent your COPD patients from falling through the cracks. They're within your reach - help protect them against pneumococcal disease with pPV23 - references 1,2

PPV coverage in COPD patients up to March 20223

Approximately 43.2%

of COPD patients were unprotected against pneumococcal disease in 20223

Order and start vaccinating today

Check PPV23 stock status

You can help protect your patients from pneumococcal disease all year round by offering PNEUMOVAX® 23 (PPV23) as part of the NHS National Immunisation Programme.1,2

Patients with COPD are at increased risk of pneumococcal disease4

Up to 1/3 of COPD exacerbations may be caused by pneumococcal bacteria (Streptococcus pneumoniae).5–7

COPD is one of the most frequent comorbid conditions present in patients with pneumonia – associated with an increased number of hospital admissions, worse outcomes and higher healthcare costs.8–10

Adults with COPD are >16x more likely to get a serious pneumococcal infection vs healthy adults.8

Unlike seasonal influenza, the chronic nature of COPD means affected individuals are at risk of pneumococcal disease all year round, not only in the winter.4

Elderly woman with eyes closed using a nebuliser

Offer/administer PNEUMOVAX® 23 at your surgery all year round, to prevent your patients from falling through the cracks1,2

Public health policy recommends PPV23 in patients with COPD, as part of the NHS National Immunisation Programme in the UK* - references 1,2

PNEUMOVAX® 23 offers immunisation against pneumococcal infections in ‘at-risk’ patients 2 years old and over with COPD.*1

You only need a single 0.5 mL dose (injected subcutaneously or intramuscularly) for most of your eligible patients.†1,2

Efficacy data

For more information on the safety of PNEUMOVAX® 23, visit our Safety information page

PPV23 is in stock and available to order via ImmForm as part of the National Immunisation Programme, and can be given to your COPD patients at any time during the year1,11,12 

Check PPV23 stock status

Find further resources on the use of PPV23 in your eligible patients on our Resources page

*PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine) is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults.2
Revaccination may be needed in certain at-risk groups. The timing and need of revaccination should be determined on the basis of official recommendations and in line with the SmPC.1,2 
Subject to supply.
CAP = community acquired pneumonia; COPD = chronic obstructive pulmonary disease; FEV = forced expiratory volume; PPV = pneumococcal polysaccharide vaccine; SmPC = Summary of Product Characteristics.


  1. The Green Book – Immunisation against infectious disease (January 2020). Chapter 25 – Pneumococcal. Available at:
  2. Pneumovax-23 Summary of Product Characteristics.
  3. UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2021 to March 2022. Available at:
  4. Torres A, et al. Thorax 2015;70(10):984–989.
  5. Shimizu K, et al. Int J Chron Obstruct Pulmon Dis. 2015;10:2009–2016.
  6. Mantero M, et al. Ther Adv Respir Dis. 2017;11(10):403–407.
  7. Wark PAB, et al. Respirol. 2013;18(6):996–1002.
  8. Restrepo MI, et al. Tuberc Respir Dis (Seoul). 2018;81(3):187–197.
  9. Froes F, et al. Int J Chron Obstruct Pulmon Dis. 2017;12:3457–3468.
  10. Walters JA. Cochrane Database Syst Rev. 2017;1(1):CD001390.
  11. UK Health Security Agency. The complete routine immunisation schedule from February 2022. National Institute for Health and Care Excellence. BNF Pneumococcal vaccine. Available at:
  12. National Institute for Health and Care Excellence. BNF Pneumococcal vaccine. Available at:

By clicking the links above you will leave the MSD Connect website and be taken to the third party websites

Supporting documentation

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website